165 related articles for article (PubMed ID: 18567697)
1. Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: implications for clinical diagnosis and doping tests.
Nguyen TV; Nelson AE; Howe CJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
Clin Chem; 2008 Aug; 54(8):1268-76. PubMed ID: 18567697
[TBL] [Abstract][Full Text] [Related]
2. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes.
Nelson AE; Howe CJ; Nguyen TV; Leung KC; Trout GJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
J Clin Endocrinol Metab; 2006 Nov; 91(11):4424-32. PubMed ID: 16912136
[TBL] [Abstract][Full Text] [Related]
3. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
[TBL] [Abstract][Full Text] [Related]
4. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
5. Demographic factors influencing the GH system: Implications for the detection of GH doping in sport.
Nelson AE; Ho KK
Growth Horm IGF Res; 2009 Aug; 19(4):327-32. PubMed ID: 19481485
[TBL] [Abstract][Full Text] [Related]
6. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.
Ehrnborg C; Lange KH; Dall R; Christiansen JS; Lundberg PA; Baxter RC; Boroujerdi MA; Bengtsson BA; Healey ML; Pentecost C; Longobardi S; Napoli R; Rosén T;
J Clin Endocrinol Metab; 2003 Jan; 88(1):394-401. PubMed ID: 12519882
[TBL] [Abstract][Full Text] [Related]
7. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
Kniess A; Ziegler E; Thieme D; Müller RK
J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes.
Nelson AE; Meinhardt U; Hansen JL; Walker IH; Stone G; Howe CJ; Leung KC; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
J Clin Endocrinol Metab; 2008 Jun; 93(6):2213-22. PubMed ID: 18381573
[TBL] [Abstract][Full Text] [Related]
9. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
[TBL] [Abstract][Full Text] [Related]
10. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
[TBL] [Abstract][Full Text] [Related]
11. Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH.
Kicman AT; Miell JP; Teale JD; Powrie J; Wood PJ; Laidler P; Milligan PJ; Cowan DA
Clin Endocrinol (Oxf); 1997 Jul; 47(1):43-50. PubMed ID: 9302371
[TBL] [Abstract][Full Text] [Related]
12. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
[TBL] [Abstract][Full Text] [Related]
13. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
[TBL] [Abstract][Full Text] [Related]
14. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting.
Healy ML; Dall R; Gibney J; Bassett E; Ehrnborg C; Pentecost C; Rosen T; Cittadini A; Baxter RC; Sönksen PH
J Clin Endocrinol Metab; 2005 Feb; 90(2):641-9. PubMed ID: 15546908
[TBL] [Abstract][Full Text] [Related]
15. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
[TBL] [Abstract][Full Text] [Related]
16. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
[TBL] [Abstract][Full Text] [Related]
17. Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report.
Sartorio A; Agosti F; Marazzi N; Maffiuletti NA; Cella SG; Rigamonti AE; Guidetti L; Di Luigi L; Muller EE
Clin Endocrinol (Oxf); 2004 Oct; 61(4):487-93. PubMed ID: 15473882
[TBL] [Abstract][Full Text] [Related]
18. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
[TBL] [Abstract][Full Text] [Related]
19. Potential parameters for the detection of hGH doping.
Kniess A; Ziegler E; Kratzsch J; Thieme D; Müller RK
Anal Bioanal Chem; 2003 Jul; 376(5):696-700. PubMed ID: 12750868
[TBL] [Abstract][Full Text] [Related]
20. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
